دورية أكاديمية
12-Lipoxygenase Inhibitor Improves Functions of Cytokine-Treated Human Islets and Type 2 Diabetic Islets.
| العنوان: | 12-Lipoxygenase Inhibitor Improves Functions of Cytokine-Treated Human Islets and Type 2 Diabetic Islets. |
|---|---|
| المؤلفون: | Ma, Kaiwen, Xiao, An, Park, So Hyun, Glenn, Lindsey, Jackson, Laura, Barot, Tatvam, Weaver, Jessica R, Taylor-Fishwick, David A, Luci, Diane K, Maloney, David J, Mirmira, Raghavendra G, Imai, Yumi, Nadler, Jerry L |
| المصدر: | Department of Emergency Medicine |
| بيانات النشر: | LVHN Scholarly Works |
| سنة النشر: | 2017 |
| المجموعة: | Lehigh Valley Health Network: LVHN Scholarly Works |
| مصطلحات موضوعية: | Adult, Case-Control Studies, Diabetes Mellitus, Type 2, Female, Glucose, Humans, In Vitro Techniques, Inflammation, Insulin, Insulin Secretion, Interferon-gamma, Interleukin-1beta, Islets of Langerhans, Lipoxygenase Inhibitors, Male, Middle Aged, Oxygen Consumption, Sulfonamides, Tumor Necrosis Factor-alpha, Young Adult, Department of Emergency Medicine, Department of Emergency Medicine Residents, Fellows and Residents, Medicine and Health Sciences |
| الوصف: | CONTEXT: The 12-lipoxygenase (12-LO) pathway produces proinflammatory metabolites, and its activation is implicated in islet inflammation associated with type 1 and type 2 diabetes (T2D). OBJECTIVES: We aimed to test the efficacy of ML355, a highly selective, small molecule inhibitor of 12-LO, for the preservation of islet function. DESIGN: Human islets from nondiabetic donors were incubated with a mixture of tumor necrosis factor α , interluekin-1β, and interferon-γ to model islet inflammation. Cytokine-treated islets and human islets from T2D donors were incubated in the presence and absence of ML355. SETTING: In vitro study. PARTICIPANTS: Human islets from organ donors aged >20 years of both sexes and any race were used. T2D status was defined from either medical history or most recent hemoglobin A1c value >6.5%. INTERVENTION: Glucose stimulation. MAIN OUTCOME MEASURES: Static and dynamic insulin secretion and oxygen consumption rate (OCR). RESULTS: ML355 prevented the reduction of insulin secretion and OCR in cytokine-treated human islets and improved both parameters in human islets from T2D donors. CONCLUSIONS: ML355 was efficacious in improving human islet function after cytokine treatment and in T2D islets in vitro. The study suggests that the blockade of the 12-LO pathway may serve as a target for both form of diabetes and provides the basis for further study of this small molecule inhibitor in vivo. |
| نوع الوثيقة: | text |
| اللغة: | unknown |
| العلاقة: | https://scholarlyworks.lvhn.org/emergency-medicine/827Test; https://pubmed.ncbi.nlm.nih.gov/28609824Test/ |
| الإتاحة: | https://scholarlyworks.lvhn.org/emergency-medicine/827Test https://pubmed.ncbi.nlm.nih.gov/28609824Test/ |
| رقم الانضمام: | edsbas.57FEA26B |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |